Delpacibart zotadirsen

RNA / oligonucleotide

Also known as KPE179, AOC 1044

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT07587242 · Avidity Biosciences, Inc.
2026-09-01 – 2030-07 · Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease, Musculoskeletal Diseases, Neuromuscular Diseases (NMD), Nervous System Diseases, Genetic Diseases, X-Linked, Hereditary, Neonatal Disease, Duchene Muscular Dystrophy, Congenital, DMD
What this study did
Phase 2 (1)
Duchenne Muscular Dystrophy
NCT06244082 · Avidity Biosciences, Inc.
2024-01-22 – 2027-04-30 · DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
What this study did
Phase 1/2 (1)
Duchenne Muscular Dystrophy
NCT05670730 · Avidity Biosciences, Inc.
2022-11-09 – 2024-11-25 · Duchenne Muscular Dystrophy, Exon 44
What this study did

Competitive landscape

This drug's own stage for Duchenne Muscular Dystrophy: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Delpacibart Zotadirsen: this drugPhase 2RNA / oligonucleotideDMD exon 44not yet gradedNo reviewed efficacy summary in this indication
GivinostatApprovedSmall moleculeHDACReliable signal
NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058)
DeramiocelPhase 3Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
RGX-202Phase 2/3Gene therapy / editingDystrophin (microdystrophin transgene)not yet gradedNo reviewed efficacy summary in this indication
BampidirsenPhase 1/2RNA / oligonucleotideDMD exon 53not yet gradedNo reviewed efficacy summary in this indication
Nivudirsen (BMN 351)Phase 1/2RNA / oligonucleotideDMD exon 51not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Delpacibart zotadirsen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 2Duchenne Muscular DystrophyActive not recruiting
Est. primary completion 2027-04-30 · NCT06244082 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 3Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease …Recruiting
Est. primary completion 2029-05 · NCT07587242 · CT.gov ↗
What to watch

See the full readout calendar ↗